Labcorp to offer first FDA-cleared blood test for initial Alzheimer’s disease assessment

Labcorp announced it will offer the nation's first blood test cleared by the FDA for the initial assessment in Alzheimer's ...
Seeking Alpha

Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw

Innovative GFAP blood biomarker test expands Labcorp's (LH) portfolio of tests for diseases including Alzheimer's disease, multiple sclerosis, glioblastoma and brain injuries BURLINGTON, N.C., April ...

Labcorp to Offer First FDA-Cleared Blood Test to Rule out Alzheimer's-Related Amyloid Pathology in Primary Care Settings

Labcorp plans to make Roche's Elecsys® pTau181 test available nationwide by early 2026 BURLINGTON, N.C., Oct. 23, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global ...
Winston-Salem Journal

Labcorp debuts blood test for early detection of Alzheimer's disease

A new Labcorp technique for early detection of Alzheimer’s disease for adults ages 50 and older has become available nationwide, the Burlington company announced last week.
Nasdaq

Labcorp Expands Precision Oncology Portfolio With Two Innovative Blood-Based Diagnostics

(RTTNews) - Labcorp (LH) Wednesday has announced a significant expansion of its precision oncology offerings with two advanced diagnostic solutions to improve cancer detection and treatment decisions.
Morningstar

Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease

Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive ...
MarketWatch

Labcorp Launches FDA-Cleared Blood Test for Alzheimer's Disease

Labcorp has launched the first blood-based in-vitro diagnostic test cleared by the Food and Drug Administration to aid in the diagnosis of Alzheimer's disease. The test--called the Lumipulse ...